Zhang Lining, Wang Qun, Wang Xiaoyan, Ding Peifang, Song Jing, Ma Chunhong, Sun Wensheng
Immunology Institute of Shandong University, Jinan, Shandong 250012, China.
Cell Mol Immunol. 2004 Feb;1(1):71-6.
CD137, a costimulatory factor of TNFR family, is expressed on activated T cells and freshly isolated mouse dendritic cells (DCs). To date, there are only limited data dealing with the expression and the effect of CD137 on human DCs. We report in this work that CD137 can coexpress with CD137L on immature peripheral blood-derived human DCs (9.77%). The mature DCs stimulated by LPS showed a much higher level of CD137 expression (36.06%). Ligation of CD137 on the surface of DCs with anti-CD137 monoclonal antibody (mAb) could enhance the direct anti-tumor effect mediated by human DCs in vitro. The agonistic anti-CD137 mAb was able to elevate by about 20% of the DC-mediated inhibition of tumor growth in five tumor cell lines. These results indicate that the appliance of anti-CD137 mAb might be used as a new strategy for tumor immunotherapy.
CD137是肿瘤坏死因子受体（TNFR）家族的共刺激因子，在活化的T细胞和新鲜分离的小鼠树突状细胞（DC）上表达。迄今为止，关于CD137在人DC上的表达及作用的数据有限。我们在本研究中报告，CD137可与CD137L在未成熟的外周血来源的人DC上共表达（9.77%）。经脂多糖（LPS）刺激的成熟DC显示出更高水平的CD137表达（36.06%）。用抗CD137单克隆抗体（mAb）连接DC表面的CD137可增强人DC在体外介导的直接抗肿瘤作用。在五种肿瘤细胞系中，激动性抗CD137 mAb能够使DC介导的肿瘤生长抑制提高约20%。这些结果表明，应用抗CD137 mAb可能成为肿瘤免疫治疗的新策略。
